DDDavid W. Dick

David W. Dick

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


David W. Dick has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Vaccine Performance Helps Explain Heterogeneity in Indirect Protection Across Influenza Vaccine Trials

    by Ashleigh R Tuite, Bryna F Warshawsky, Lindsay Friedman, Jeffrey C Kwong, David W Dick

  • Open Access

    SARS-CoV-2 booster vaccine dose significantly extends humoral immune response half-life beyond the primary series

    by Chapin S. Korosec, David W. Dick, Iain R. Moyles, James Watmough

    SARS-CoV-2 lipid nanoparticle mRNA vaccines continue to be administered as the predominant prophylactic measure to reduce COVID-19 disease pathogenesis. Quantifying the kinetics of the secondary immune response from subsequent doses beyond the primary series and understanding how dose-dependent immune waning kinetics vary as a function of age, sex, and various comorbidities remains an important question. We study anti-spike IgG waning kinetics in 152 individuals who received an mRNA-based primary series (first two doses) and a subset of 137 individuals who then received an mRNA-based booster dose. We find the booster dose elicits a 71–84% increase in the median Anti-S half life over that of the primary series. We find the Anti-S half life for both primary series and booster doses decreases with age. However, we stress that although chronological age continues to be a good proxy for vaccine-induced humoral waning, immunosenescence is likely not the mechanism, rather, more likely the mechanism is related to the presence of noncommunicable diseases, which also accumulate with age, that affect immune regulation. We are able to independently reproduce recent observations that those with pre-existing asthma exhibit a stronger primary series humoral response to vaccination than compared to those that do not, and further, we find this result is sustained for the booster dose. Finally, via a single-variate Kruskal-Wallis test we find no difference between male and female humoral decay kinetics, however, a multivariate approach utilizing Least Absolute Shrinkage and Selection Operator (LASSO) regression for feature selection reveals a statistically significant (p $$<1\times 10^{-3}$$ < 1 × 10 - 3 ), albeit small, bias in favour of longer-lasting humoral immunity amongst males.


  • Open Access

    SARS-CoV-2 booster vaccine dose significantly extends humoral immune response half-life beyond the primary series

    by Chapin S. Korosec, David W. Dick, Iain R. Moyles, James Watmough

    SARS-CoV-2 lipid nanoparticle mRNA therapeutics continue to be administered as the predominant therapeutic intervention to reduce COVID-19 disease pathogenesis. Quantifying the kinetics of the secondary immune response from subsequent doses beyond the primary series, and understanding how dose-dependent immune waning kinetics vary as a function of age, sex, and various comorbidities, remains an important question. We study anti-spike IgG waning kinetics in 152 individuals who received an mRNA-based primary series and a subset of 137 individuals who then received a booster dose. We find the booster dose elicits a 71-84% increase in the median Anti-S half life over that of the primary series. We find the Anti-S half life for both primary series and booster doses drops as a function of increased year of age. However, we stress that although chronological age continues to be a good proxy for vaccine-induced humoral waning, immunosenescence is likely not the mechanism, rather, more likely the mechanism is related to the presence of noncommunicable diseases, which also accumulate with age, that affect immune regulation. We are able to independently reproduce recent observations that those with pre-existing asthma exhibit a stronger primary series humoral response to vaccination than compared to those that do not, and further find this result is sustained for the booster dose. Finally, via a single-variate KruskalWallis Test we find no difference between male and female decay kinetics, however, a multivariate approach utilizing Lasso regression for feature selection reveals a statistically significant (p-value−3 ), albeit small, bias in favour of longer-lasting humoral immunity amongst males.

  • Open Access

    Canadian Covid-19 pandemic public health mitigation measures at the province level

    by Anna Akanteva, David W. Dick, Shirin Amiraslani, Jane M. Heffernan

    The Covid-19 pandemic has prompted governments across the world to enforce a range of public health interventions. We introduce the Covid-19 Policy Response Canadian tracker (CPRCT) database that tracks and records implemented public health measures in every province and territory in Canada. The implementations are recorded on a four-level ordinal scale (0–3) for three domains, (Schools, Work, and Other), capturing differences in degree of response. The data-set allows the exploration of the effects of public health mitigation on the spread of Covid-19, as well as provides a near-real-time record in an accessible format that is useful for a diverse range of modeling and research questions.


  • Multiple cohort study of hospitalized SARS-CoV-2 in-host infection dynamics: Parameter estimates, identifiability, sensitivity and the eclipse phase profile

    by Chapin S. Korosec, Matthew I. Betti, David W. Dick, Hsu Kiang Ooi, Iain R. Moyles, Lindi M. Wahl, Jane M. Heffernan


  • Open Access

    Modeling waning and boosting of COVID-19 in Canada with vaccination

    by Lauren Childs, David W. Dick, Zhilan Feng, Jane M. Heffernan, Jing Li, Gergely Röst


  • Open Access

    COVID-19 Seroprevalence in Canada Modelling Waning and Boosting COVID-19 Immunity in Canada a Canadian Immunization Research Network Study

    by David W. Dick, Lauren Childs, Zhilan Feng, Jing Li, Gergely Röst, David L. Buckeridge, Nick H. Ogden, Jane M. Heffernan

    COVID-19 seroprevalence changes over time, with infection, vaccination, and waning immunity. Seroprevalence estimates are needed to determine when increased COVID-19 vaccination coverage is needed, and when booster doses should be considered, to reduce the spread and disease severity of COVID-19 infection. We use an age-structured model including infection, vaccination and waning immunity to estimate the distribution of immunity to COVID-19 in the Canadian population. This is the first mathematical model to do so. We estimate that 60–80% of the Canadian population has some immunity to COVID-19 by late Summer 2021, depending on specific characteristics of the vaccine and the waning rate of immunity. Models results indicate that increased vaccination uptake in age groups 12–29, and booster doses in age group 50+ are needed to reduce the severity COVID-19 Fall 2021 resurgence.


  • Open Access

    Barrier Gesture Relaxation during Vaccination Campaign in France: Modelling Impact of Waning Immunity

    by Carole Vignals, David W. Dick, Rodolphe Thiébaut, Linda Wittkop, Mélanie Prague, Jane M. Heffernan

    Non-pharmaceutical interventions have been implemented intermittently for more than a year in most countries of the world to mitigate the COVID-19 epidemic. In France, while the vaccination campaign is progressing, the French government has decided to remove many public health restrictions such as business closure, lockdowns, and curfews. Nonetheless, social distancing, mask wearing, and hand washing (also called barrier gestures) are still recommended. We utilize an age-structured compartmental SEIR model that takes into account the SARS-CoV-2 waning immunity, vaccination, and increased transmissibility from variants of concern to estimate if barrier gestures can be relaxed without causing a resurgence of severe infections. This model assumes that the susceptibility to infection is a function of immunity status, which depends on initial infection severity and vaccination status. It is calibrated on confirmed COVID-19 cases from the French surveillance database, and accounts for changes in contact behaviors due to the implementation of nation-wide public health policies. We study the partial and full relaxation of barrier gestures occurring from August to December 2021 under various immunity duration assumptions. Maintaining the application of barrier gestures appears essential to avoid a resurgence of severe infections that would exceed French health care capacities, while surmounting vaccine hesitancy represents the key to consider their relaxation. Immunity duration assumptions significantly influence the short-term dynamic of the epidemic, which should be considered for further modelling.